News Sentiment

ERNA sentiment intelligence

Eterna Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.42 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.9% over one week, +3.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 5.9% Price confirming higher
Trend fit Trend inactive 3.5% over four weeks
Fair value -98.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 32
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 6
GlobeNewswire 5
Moomoo 4
Quiver Quantitative 3
MT Newswires 2
Benzinga 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 14
Regulatory and legal 4
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Intellectia AI Direct company coverage

ERNA Should I Buy

An Intellectia AI analysis suggests that Ernexa Therapeutics Inc (ERNA) is not a strong buy for long-term beginner investors despite a favorable analyst price target of $30. The company shows potential with innovative immune-oncology approaches and clinical trial advancements for

Tone
Negative 39/100
Event
Analyst action
Published
19 Jun 2026 07:11
Source
Intellectia AI
Stock Titan Direct company coverage

Ernexa sees ERNA-101 enter first-in-human study in Q4 2026

Ernexa Therapeutics (Nasdaq: ERNA) announced significant progress for its lead oncology candidate, ERNA-101, targeting an Investigational New Drug (IND) submission in Q3 2026 and a first-in-human Phase 1 study by Q4 2026. Preclinical data for ERNA-101 combined with PD-1 blockade

Tone
Positive 73/100
Event
Regulatory and legal
Published
17 Jun 2026 08:47
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Ernexa Therapeutics Inc. – NASDAQ:ERNAW

This article provides limited information on the number of shareholders for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a stub or a placeholder from TradingView's financial data section, indicating that specific shareholder figures are not immediately presented in

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 05:10
Source
TradingView
Market source Direct company coverage

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Ernexa Therapeutics discussed the significant unmet need in ovarian cancer and the potential of their ERNA-101 program during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion highlighted ERNA-101's dual mechanism, off-the-shelf scalability, and poten

Tone
Positive 70/100
Event
Market update
Published
10 Jun 2026 03:09
Source
Market source
GlobeNewswire Direct company coverage

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need,

Ernexa Therapeutics recently participated in a Virtual Investor KOL Connect segment, where Dr. Ira Winer discussed the significant unmet need in ovarian cancer and the challenges of treating immunologically "cold" tumors. The discussion highlighted Ernexa's ERNA-101 program and i

Tone
Positive 72/100
Event
Market update
Published
09 Jun 2026 08:41
Source
GlobeNewswire
Intellectia AI Direct company coverage

ERNA Stock News Today | Earnings, Events & Price Alerts

This article provides recent news and events related to ERNA (Ernexa Therapeutics), including updates on its ovarian cancer treatment ERNA-101 and its planned IND submission. Key news highlights involve significant loss narrowing, positive therapy results, and a recent 1-for-25 r

Tone
Positive 72/100
Event
Earnings
Published
03 Jun 2026 09:39
Source
Intellectia AI
Stock Titan Direct company coverage

Ernexa readies ERNA-101 experimental therapy for first human tests, IND Q3 2026

Ernexa Therapeutics announced significant progress for its lead therapeutic candidate, ERNA-101, by completing manufacturing milestones including process development and transitioning to GMP manufacturing. These achievements position the company for a planned Investigational New

Tone
Positive 63/100
Event
Regulatory and legal
Published
28 May 2026 09:10
Source
Stock Titan